1887

Chapter 31 : Innate Humoral Immunity to Fungi

Author: Thomas R. Kozel1
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: Department of Microbiology and Immunology, University of Nevada School of Medicine, Reno, NV 59557
Content Type: Monograph
Publication Year: 2006

Category: Fungi and Fungal Pathogenesis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Innate Humoral Immunity to Fungi, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815776/9781555813680_Chap31-1.gif /docserver/preview/fulltext/10.1128/9781555815776/9781555813680_Chap31-2.gif

Abstract:

The humoral innate immune system has three key elements: the complement system; pattern recognition by the collectin protein, mannan-binding lectin (MBL); and naturally occurring antibodies that are reactive with carbohydrate antigens found in the fungal cell wall. This chapter considers each of the three systems of innate humoral immunity in turn, with an emphasis on recognition, amplification cascades, interaction between the systems, and the similarities and differences between fungi in their interactions with these systems. Normal human serum contains antibodies that are reactive with the cell wall. Binding of these antibodies is followed by activation of the classical pathway with subsequent covalent binding of C3 fragments to the cell surface. Complement activation and the biological consequences of complement activation have been examined for most of the pathogenic fungi. It is likely that MBL is one of several redundant systems that provide host resistance to pathogenic fungi. There are several potential mechanisms by which pathogenic fungi might evade surveillance by innate humoral immunity. The candidal integrin-like protein probably has several properties that might contribute to virulence including molecular mimicry to avoid phagocytosis and adhesion to host tissues. The alternative pathway, MBL, and natural antibodies probably have redundant functions. As a consequence, it is possible that the host could lose one of these activities without loss of innate resistance.

Citation: Kozel T. 2006. Innate Humoral Immunity to Fungi, p 457-469. In Heitman J, Filler S, Edwards, Jr. J, Mitchell A (ed), Molecular Principles of Fungal Pathogenesis. ASM Press, Washington, DC. doi: 10.1128/9781555815776.ch31

Key Concept Ranking

Complement System
0.633066
Infection and Immunity
0.5707711
Innate Immune System
0.52056456
Complement Receptor Type 1
0.46326545
0.633066
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555815776.ch31
1. Ashman, R. B.,, J. M. Papadimitriou,, A. Fulurija,, K. E. Drysdale,, C. S. Farah,, O. Naidoo, and, T. Gotjamanos. 2003. Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice. Microb. Pathog. 34: 103– 113.
2. Babula, O.,, G. Lazdane,, J. Kroica,, W. J. Ledger, and, S. S. Witkin. 2003. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin. Infect. Dis. 37: 733– 737.
3. Bendel, C. M., and, M. K. Hostetter. 1993. Distinct mechanisms of epithelial adhesion for Candida albicans and Candida tropicalis. Identification of the participating ligands and development of inhibitory peptides. J. Clin. Investig. 92: 1840– 1849.
4. Bendel, C. M.,, J. St. Sauver,, S. Carlson, and, M. K. Hostetter. 1995. Epithelial adhesion in yeast species: correlation with surface expression of the integrin analog. J. Infect. Dis. 171: 1660– 1663.
5. Brawner, D. L., and, J. E. Cutler. 1986. Ultrastructural and biochemical studies of two dynamically expressed cell surface determinants on Candida albicans. Infect. Immun. 51: 327– 336.
6. Brawner, D. L., and, J. E. Cutler. 1985. Changes in surface topography of Candida albicans during morphogenesis. J. Med. Vet. Mycol. 23: 389– 393.
7. Budzko, D. B., and, R. Negroni. 1975. Hemolytic, cytotoxic and complement inactivating properties of extracts of different species of aspergillus. Mycopathologia 57: 23– 26.
8. Byron, J. K.,, K. V. Clemons,, J. H. McCusker,, R. W. Davis, and, D. A. Stevens. 1995. Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice. Infect. Immun. 63: 478– 485.
9. Calich, V. L. G.,, T. L. Kipnis,, M. Mariano,, C. F. Neto, and, W. D. da Silva. 1979. The activation of the complement system by Paracoccidioides brasiliensis in vitro: its opsonic effect and possible significance for an in vivo model of infection. Clin. Immunol. Immunopathol. 12: 20– 30.
10. Castaldo, P.,, R. J. Stratta,, R. P. Wood,, R. S. Markin,, K. D. Patil,, M. S. Shaefer,, A. N. Langnas,, E. C. Reed,, S. Li,, T. J. Pillen, and, B. W. Shaw. 1998. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch. Surg. 126: 149– 156.
11. Chenoweth, D. E. 1986. Complement mediators of inflammation, p. 63–86. In G. D. Ross (ed.), Immunobiology of the Complement System: an Introduction for Research and Clinical Medicine. Academic Press, Inc., Orlando, Fla.
12. Cherniak, R.,, H. Valafar,, L. C. Morris, and, F. Valafar. 1998. Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. Clin. Diagn. Lab. Immunol. 5: 146– 159.
13. Chiba, H.,, H. Sano,, D. Iwaki,, S. Murakami,, T. Takahashi,, M. Konishi,, H. Takahashi, and, Y. Kuroki. 2004. Rat mannose-binding protein A binds CD14. Infect. Immun. 69: 1587– 1592.
14. Crosdale, D. J.,, K. V. Poulton,, W. E. Ollier,, W. Thomson, and, D. W. Denning. 2001. Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J. Infect. Dis. 184: 653– 656.
15. Cross, C. E., and, G. J. Bancroft. 1995. Ingestion of acapsular Cryptococcus neoformans occurs via mannose and β-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form. Infect. Immun. 63: 2604– 2611.
16. Dahl, M. V., and, R. Carpenter. 1986. Polymorphonuclear leukocytes, complement, and Trichophyton rubrum. J. Investig. Dermatol. 86: 138– 141.
17. Davies, S. F.,, D. P. Clifford,, J. R. Hoidal, and, J. E. Repine. 1982. Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonu-clear leukocytes and monocytes. J. Infect. Dis. 145: 870– 874.
18. De Bracco, M. M.,, D. B. Budzko, and, R. Negroni. 1976. Mechanisms of activation of complement by extracts of Aspergillus fumigatus. Clin. Immunol. Immunopathol. 5: 333– 339.
19. de Saint Basile, G.,, A. Durandy,, G. Somme, and, C. Griscelli. 1987. Idiotypy of human anti- Candida albi-cans antibodies: recurrence, presence of a cross-reactive autoanti-idiotypic-like activity, and role in the induction of specific in vitro antibody response. J. Immunol. 138: 417– 422.
20. Diamond, R. D., and, N. F. Erickson III. 1982. Chemotaxis of human neutrophils and monocytes induced by Cryptococcus neoformans. Infect. Immun. 38: 380– 382.
21. Diamond, R. D.,, J. E. May,, M. A. Kane,, M. M. Frank, and, J. E. Bennett. 1974. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J. Immunol. 112: 2260– 2270.
22. DiCarlo, F. J., and, J. V. Fiore. 1958. On the composition of zymosan. Science 127: 756– 757.
23. Drickamer, K.,, M. S. Dordal, and, L. Reynolds. 1986. Mannose-binding proteins isolated from rat liver contain carbohydrate-recognition domains linked to collagenous tails. J. Biol. Chem. 261: 6878– 6887.
24. Edwards, J. E., Jr.,, T. A. Gaither,, J. J. O’Shea,, D. Rotrosen,, T. J. Lawley,, S. A. Wright,, M. M. Frank, and, I. Green. 1986. Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J. Immunol. 137: 3577– 3583.
25. Ehrlich, P., and, H. Sachs. 1902. Ueber die vielheit der complemente des serums. Berl. Klin. Wochenschr. 39: 297– 299.
26. Faux, J. A.,, A. E. Agbarakwe,, S. A. Misbah, and, H. M. Chapel. 1992. A comparison of specific IgG antibody levels to the cell wall mannan of Candida albicans in normal individuals and in patients with primary antibody deficiency. J. Immunol. Methods 153: 167– 172.
27. Ferrante, A., and, Y. H. Thong. 1979. Requirement of heat-labile opsonins for maximal phagocytosis of Candida albicans. Sabouraudia 17: 293– 297.
28. Fizpatrick, F. W., and, F. J. DiCarlo. 1964. Zymosan. Ann. N. Y. Acad. Sci. 118: 235– 261.
29. Fujita, T.,, Y. Endo, and, M. Nonaka. 2004. Primitive complement system—recognition and activation. Mol. Immunol. 41: 103– 111.
30. Gale, C. A.,, C. M. Bendel,, M. McClellan,, M. Hauser,, J. M. Becker,, J. Berman, and, M. K. Hostetter. 1998. Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1. Science 279: 1355– 1358.
31. Galgiani, J. N.,, R. A. Isenberg, and, D. A. Stevens. 1978. Chemotaxigenic activity of extracts from the mycelial and spherule phases of Coccidioides immitis for human polymorphonuclear leukocytes. Infect. Immun. 21: 862– 865.
32. Galgiani, J. N.,, P. Yam,, L. D. Petz,, P. L. Willams, and, D. A. Stevens. 1980. Complement activation by Coccidioides immitis: in vitro and clinical studies. Infect. Immun. 28: 944– 949.
33. Garred, P.,, H. O. Madsen,, B. Hofmann, and, A. Svejgaard. 1995. Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet 346: 941– 943.
34. Gates, M. A.,, P. Thorkildson, and, T. R. Kozel. 2004. Molecular architecture of the Cryptococcus neoformans capsule. Mol. Microbiol. 52: 13– 24.
35. Ghiran, I.,, S. F. Barbashov,, L. B. Klickstein,, S. W. Tas,, J. C. Jensenius, and, A. Nicholson-Weller. 2000. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J. Exp. Med. 192: 1797– 1808.
36. Gilmore, B. J.,, E. M. Retsinas,, J. S. Lorenz, and, M. K. Hostetter. 1988. An iC3b receptor on Candida albicans: structure, function, and correlates for pathogenicity. J. Infect. Dis. 157: 38– 46.
37. Goren, M. B., and, J. Warren. 1968. Immunofluorescence studies of reactions at the cryptococcal capsule. J. Infect. Dis. 118: 215– 229.
38. Greenfield, R. A.,, J. L. Stephens,, M. J. Bussey, and, J. M. Jones. 1983. Quantitation of antibody to Candida mannan by enzyme-linked immunosorbent assay. J. Lab. Clin. Med. 101: 758– 771.
39. Han, Y., and, J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63: 2714– 2719.
40. Hector, R. F.,, E. Yee, and, M. S. Collins. 1990. Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis. Infect. Immun. 58: 1476– 1478.
41. Heidenreich, F., and, M. P. Dierich. 1985. Candida albi-cans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect. Immun. 50: 598– 600.
42. Horstmann, R. D.,, M. K. Pangburn, and, H. J. Muller-Eberhard. 1985. Species specificity of recognition by the alternative pathway of complement. J. Immunol. 134: 1101– 1104.
43. Iobst, S. T.,, M. R. Wormald,, W. I. Weis,, R. A. Dwek, and, K. Drickamer. 1994. Binding of sugar ligands to Ca 2+-dependent animal lectins. I. Analysis of mannose binding by site-directed mutagenesis and NMR. J. Biol. Chem. 269: 15505– 15511.
44. Ip, W. K., and, Y. L. Lau. 2004. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J. Infect. Dis. 190: 632– 640.
45. Jack, D. L.,, N. J. Klein, and, M. W. Turner. 2001. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol. Rev. 180: 86– 99.
46. Jensenius, J. C.,, R. H. Jensen,, K. McGwire,, J. L. Larsen, and, S. Thiel. 2003. Recombinant mannan-binding lectin (MBL) for therapy. Biochem. Soc. Trans. 31: 763– 767.
47. Jones, J. M. 1980. Quantitation of antibody against cell wall mannan and a major cytoplasmic antigen of Candida in rabbits, mice, and humans. Infect. Immun. 30: 78– 89.
48. Kawasaki, N.,, T. Kawasaki, and, I. Yamashina. 1983. Isolation and characterization of a mannan-binding protein from human serum. J. Biochem. (Tokyo) 94: 937– 947.
49. Kawasaki, T.,, R. Etoh, and, I. Yamashina. 1978. Isolation and characterization of a mannan-binding protein from rabbit liver. Biochem. Biophys. Res. Commun. 81:1018.
50. Keller, R. G.,, G. S. T. Pfrommer, and, T. R. Kozel. 1994. Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect. Immun. 62: 215– 220.
51. Kitz, D. J.,, P. D. Stahl, and, J. R. Little. 1992. The effect of a mannose binding protein on macrophage interactions with Candida albicans. Cell. Mol. Biol. 38: 407– 412.
52. Kozel, T. R.,, R. R. Brown, and, G. S. T. Pfrommer. 1987. Activation and binding of C3 by Candida albicans. Infect. Immun. 55: 1890– 1894.
53. Kozel, T. R.,, R. S. MacGill,, A. Percival, and, Q. Zhou. 2004. Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect. Immun. 72: 209– 218.
54. Kozel, T. R., and, G. S. T. Pfrommer. 1986. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect. Immun. 52: 1– 5.
55. Kozel, T. R.,, A. Tabuni,, B. J. Young, and, S. M. Levitz. 1996. Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells. Infect. Immun. 64: 2336– 2338.
56. Kozel, T. R.,, L. C. Weinhold, and, D. M. Lupan. 1996. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect. Immun. 64: 3360– 3368.
57. Kozel, T. R.,, M. A. Wilson,, T. P. Farrell, and, S. M. Levitz. 1989. Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae. Infect. Immun. 57: 3412– 3417.
58. Kozel, T. R.,, M. A. Wilson, and, J. W. Murphy. 1991. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect. Immun. 59: 3101– 3110.
59. Kozel, T. R.,, M. A. Wilson,, G. S. T. Pfrommer, and, A. M. Schlageter. 1989. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect. Immun. 57: 1922– 1927.
60. Kozel, T. R.,, M. A. Wilson, and, W. H. Welch. 1992. Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 60: 3122– 3127.
61. Kuhlman, M.,, K. Joiner, and, R. A. B. Ezekowitz. 1989. The human mannose-binding protein functions as an opsonin. J. Exp. Med. 169: 1733– 1745.
62. Law, S. K., and, R. P. Levine. 1977. Interaction between the third complement protein and cell surface macromolecules. Proc. Natl. Acad. Sci. USA 74: 2701– 2705.
63. Laxalt, K. A., and, T. R. Kozel. 1979. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans. Infect. Immun. 26: 435– 440.
64. Lee, R. T.,, Y. Ichikawa,, M. Fay,, K. Drickamer,, M. C. Shao, and, Y. C. Lee. 1991. Ligand-binding characteristics of rat serum-type mannose-binding protein (MBPA). Homology of binding site architecture with mammalian and chicken hepatic lectins. J. Biol. Chem. 266: 4810– 4815.
65. Lee, S. J.,, G. Gonzalez-Aseguinolaza, and, M. C. Nussenzweig. 2002. Disseminated candidiasis and hepatic malarial infection in mannose-binding-lectin-A-deficient mice. Mol. Cell. Biol. 22: 8199– 8203.
66. Lehmann, P. F., and, E. Reiss. 1980. Comparison by ELISA of serum anti- Candida albicans mannan IgG levels of a normal population and in diseased patients. Mycopathologia 70: 89– 93.
67. Lovchik, J. A., and, M. F. Lipscomb. 1993. Role of C5 and neutrophils in the pulmonary intravascular clearance of circulating Cryptococcus neoformans. J. Respir. Cell Mol. Biol. 9: 617– 627.
68. Lu, J.,, S. Thiel,, H. Wiedemann,, R. Timpl, and, K. B. M. Reid. 1990. Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the pro-enzyme C1r 2C1s 2 complex, of the classical pathway of complement, without involvement of C1q. J. Immunol. 144: 2287– 2294.
69. Lyon, F. L.,, R. F. Hector, and, J. E. Domer. 1986. Innate and acquired immune responses against Candida albi-cans in congenic B10.D2 mice with deficiency of the C5 complement component. J. Med. Vet. Mycol. 24: 359– 367.
70. Macher, A. M.,, J. E. Bennett,, J. E. Gadek, and, M. M. Frank. 1978. Complement depletion in cryptococcal sepsis. J. Immunol. 120: 1686– 1690.
71. Malhotra, R.,, S. Thiel,, K. B. M. Reid, and, R. B. Sim. 1990. Human leukocyte C1q receptor binds other soluble proteins with collagen domains. J. Exp. Med. 172: 955– 959.
72. McCormack, F. X.,, R. Gibbons,, S. R. Ward,, A. Kuzmenko, and, G. S. Deepe. 2003. Macrophage-independent fungicidal action of the pulmonary collectins. J. Biol. Chem. 278: 36250– 36256.
73. Meri, T.,, A. M. Blom,, A. Hartmann,, D. Lenk,, S. Meri, and, P. F. Zipfel. 2004. The hyphal and yeast forms of Candida albicans bind the complement regulator C3b-binding protein. Infect. Immun. 72: 6633– 6641.
74. Meri, T.,, A. Hartmann,, D. Lenk,, R. Eck,, R. Wurzner,, J. Hellwage,, S. Meri, and, P. F. Zipfel. 2002. The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect. Immun. 70: 5185– 5192.
75. Miller, M. E.,, J. Seals,, R. Kaye, and, L. C. Levitsky. 1968. A familial, plasma associated defect of phagocytosis: a new cause of recurrent bacterial infections. Lancet ii: 60– 63.
76. Mitchell, T. G., and, L. Friedman. 1972. In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans. Infect. Immun. 5: 491– 498.
77. Morelli, R., and, L. T. Rosenberg. 1971. Role of complement during experimental Candida infection in mice. Infect. Immun. 3: 521– 523.
78. Morrison, R. P., and, J. E. Cutler. 1981. In vitro studies of the interaction of murine phagocytic cells with Candida albicans. J. Reticuloendothel. Soc. 29: 23– 34.
79. Mullighan, C. G.,, S. E. Marshall, and, K. I. Welsh. 2000. Mannose binding lectin polymorphisms are associated with early age of disease onset and autoimmunity in common variable immunodeficiency. Scand. J. Immunol. 51: 111– 122.
80. Munk, M. E., and, W. Dias Da Silva. 1992. Activation of human complement system Paracoccidioides brasiliensis and its deposition on the yeast form cell surface. J. Med. Vet. Mycol. 30: 481– 484.
81. Munk, M. E.,, A. Kajdacsy-Balla,, G. Del Negro,, L. C. Cuce, and, W. Dias Da Silva. 1992. Activation of human complement system in paracoccidioidomycosis. J. Med. Vet. Mycol. 30: 317– 321.
82. Neth, O.,, I. Hann,, M. W. Turner, and, N. J. Klein. 2001. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 358: 614– 618.
83. Neth, O.,, D. L. Jack,, A. W. Dodds,, H. Holzel,, N. J. Klein, and, M. W. Turner. 2000. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect. Immun. 68: 688– 693.
84. Pereira, H. A., and, C. S. Hosking. 1984. The role of complement and antibody in opsonization and intracellular killing of Candida albicans. Clin. Exp. Immunol. 57: 307– 314.
85. Peterslund, N. A.,, C. Koch, and, J. C. Jensenius. 2001. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 358: 637– 638.
86. Pillemer, L.,, L. Blum,, I. H. Lepow,, O. A. Ross,, E. W. Todd, and, A. C. Wardlaw. 1954. Properdin system and immunity: demonstration and isolation of new serum protein, properdin, and its role in immune phenomena. Science 120: 279– 285.
87. Pillemer, L.,, L. Blum,, I. H. Lepow,, L. Wurz, and, E. W. Todd. 1956. The properdin system and immunity. III. The zymosan assay of properdin. J. Exp. Med. 103: 1– 13.
88. Pillemer, L., and, E. E. Ecker. 1941. Anticomplementary factor in fresh yeast. J. Biol. Chem. 137: 139– 142.
89. Presanius, J. S.,, M. Kojima, and, R. B. Sim. 2003. Biochemistry and genetics of mannan-binding lectin (MBL). Biochem. Soc. Trans. 31: 748– 752.
90. Ray, T. L., and, K. D. Wuepper. 1976. Activation of the alternative (properdin) pathway of complement by Candida albicans and related species. J. Investig. Dermatol. 67: 700– 703.
91. Rhodes, J. C. 1985. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia 23: 225– 234.
92. Robbins, J. B.,, R. Schneerson,, M. P. Glode,, W. Vann,, M. S. Schiffer,, T.-Y. Liu,, J. C. Parke, Jr., and, C. Huntley. 1975. Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria. J. Allergy Clin. Immunol. 56: 141– 151.
93. Stratta, R. J.,, M. S. Shaefer,, K. A. Cushing,, R. S. Markin,, E. C. Reed,, A. N. Langnas,, T. J. Pillen, and, B. W. Shaw. 1992. A randomized prospective trial of acyclovar and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch. Surg. 127: 55– 64.
94. Sturtevant, J., and, J. P. Latgé. 1992. Participation of complement in the phagocytosis of the conidia of Aspergillus fumigatus by human polymorphonuclear cells. J. Infect. Dis. 166: 580– 586.
95. Sturtevant, J. E., and, J. P. Latgé. 1992. Interactions between conidia of Aspergillus fumigatus and human complement component C3. Infect. Immun. 60: 1913– 1918.
96. Sumiya, M., and, J. A. Summerfield. 1997. Mannose-binding protein, genetic variants and the risk of infection. Q. J. Med. 89: 723– 726.
97. Summerfield, J. A. 2003. Clinical potential of mannose-binding lectin-replacement therapy. Biochem. Soc. Trans. 31: 770– 773.
98. Summerfield, J. A.,, S. Ryder,, M. Sumiya,, M. Thursz,, A. Gorchein,, M. A. Monteil, and, M. W. Turner. 1995. Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 345: 886– 889.
99. Swan, J. W.,, M. V. Dahl,, P. A. Coppo, and, D. E. Hammerschmidt. 1983. Complement activation by Trichophyton rubrum. J. Investig. Dermatol. 80: 156– 158.
100. Tabona, P.,, A. Mellor, and, J. A. Summerfield. 1995. Mannose binding protein is involved in the first-line host defense: evidence from transgenic mice. Immunology 85: 153– 159.
101. Tagami, H.,, N. Natsume,, T. Aoshima,, F. Inuoe,, S. Suehisa, and, M. Yamada. 1982. Analysis of transepidermal leukocyte chemotaxis in experimental dermatophytosis in guinea pigs. Arch. Dermatol. Res. 273: 205– 217.
102. Thiel, S.,, U. Holmskov,, L. Hviid,, S. B. Laursen, and, J. C. Jensenius. 1992. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin. Exp. Immunol. 90: 31– 35.
103. Thiel, S.,, S. V. Petersen,, T. Vorup-Jensen,, M. Matsushita,, T. Fujita,, C. M. Stover,, W. J. Schwaeble, and, J. C. Jensenius. 2000. Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL-associated serine proteases 1 and 2, and the MBL-associated protein MAp19. J. Immunol. 165: 878– 887.
104. Thiel, S.,, T. Vorup-Jensen,, C. M. Stover,, W. Schwaeble,, S. B. Laursen,, K. Poulsen,, A. C. Willis,, P. Eggleton,, S. Hansen,, U. Holmskov,, K. B. Reid, and, J. C. Jensenius. 1997. A second serine protease associated with mannan-binding lectin that activates complement. Nature 386: 506– 510.
105. Thong, Y. H., and, A. Ferrante. 1978. Alternative pathway of complement activation by Candida albicans. Aust. N. Z. J. Med. 8: 620– 622.
106. Townsend, R.,, R. C. Read,, M. W. Turner,, N. J. Klein, and, D. L. Jack. 2001. Differential recognition of obligate anaerobic bacteria by human mannose-binding lectin. Clin. Exp. Immunol. 124: 223– 228.
107. Truelsen, K.,, T. Young, and, T. R. Kozel. 1992. In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans. Infect. Immun. 60: 1– 4.
108. Tsai, H. F.,, R. G. Washburn,, Y. C. Chang, and, K. J. Kwon-Chung. 1997. Aspergillus fumigatus arp1 modulates conidial pigmentation and complement deposition. Mol. Microbiol. 26: 175– 183.
109. Tsai, H.-F.,, Y. C. Chang,, R. G. Washburn,, M. H. Wheeler, and, K. J. Kwon-Chung. 1998. The developmentally regulated alb1 gene of Aspergillus fumigatus: its role in modulation of conidial morphology and virulence. J. Bacteriol. 180: 3031– 3038.
110. van de Wetering, J. K.,, L. M. G. van Golde, and, J. J. Batenburg. 2004. Collectins. Players of the innate immune system. Eur. J. Biochem. 271: 1229– 1249.
111. von Dungern, E. 1900. Beitrage zur Immunitatslehre. Munch. Med. Wochenschr. 47: 677– 680.
112. Washburn, R. G.,, D. J. DeHart,, D. E. Agwu,, B. J. Bryant-Varela, and, N. C. Julian. 1990. Aspergillus fumigatus complement inhibitor: production, characterization, and purification by hydrophobic interaction and thin-layer chromatography. Infect. Immun. 58: 3508– 3515.
113. Washburn, R. G.,, C. H. Hammer, and, J. E. Bennett. 1986. Inhibition of complement by culture super-natants of Aspergillus fumigatus. J. Infect. Dis. 154: 944– 951.
114. Weis, W. I.,, K. Drickamer, and, W. A. Hendrickson. 1992. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 360: 127– 134.
115. Wilson, M. A., and, T. R. Kozel. 1992. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 60: 754– 761.
116. Young, B. J., and, T. R. Kozel. 1993. Effects of strain variation, serotype and structural modification on the kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect. Immun. 61: 2966– 2972.
117. Zaragoza, O.,, C. P. Taborda, and, A. Casadevall. 2004. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur. J. Immunol. 33: 1957– 1967.
118. Zhang, M. X.,, T. T. Brandhorst,, T. R. Kozel, and, B. S. Klein. 2001. Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast. Infect. Immun. 69: 7559– 7564.
119. Zhang, M. X., and, B. Klein. 1997. Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis. Infect. Immun. 65: 1849– 1855.
120. Zhang, M. X., and, T. R. Kozel. 1998. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infect. Immun. 66: 4845– 4850.
121. Zhang, M. X.,, D. M. Lupan, and, T. R. Kozel. 1997. Mannan-specific IgG antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect. Immun. 65: 3822– 3827.

Tables

Innate Humoral Immunity to Fungi
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815776.ch31-1,webId=/content/author/10.1128/9781555815776.ch31-1,properties={foaf_givenname=Thomas R., foaf_name=Thomas R. Kozel, foaf_surname=Kozel, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815776.ch31-aff1]]}]]
Citation: Kozel T. 2006. Innate Humoral Immunity to Fungi, p 457-469. In Heitman J, Filler S, Edwards, Jr. J, Mitchell A (ed), Molecular Principles of Fungal Pathogenesis. ASM Press, Washington, DC. doi: 10.1128/9781555815776.ch31
/content/10.1128/9781555815776.ch31.ch31tab01
Table 1.
Biological consequences of activation of the complement system by pathogenic fungi
Generic image for table
Table 1.

Biological consequences of activation of the complement system by pathogenic fungi

Citation: Kozel T. 2006. Innate Humoral Immunity to Fungi, p 457-469. In Heitman J, Filler S, Edwards, Jr. J, Mitchell A (ed), Molecular Principles of Fungal Pathogenesis. ASM Press, Washington, DC. doi: 10.1128/9781555815776.ch31

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error